Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BioAxone Therapeutic

Request full access

BioAxone Therapeutic is neuroscience company focused on the development and commercialization of technologies that target Rho signaling

Montreal, CanadaFounded 2000Biotech & Life Sciences

About BioAxone Therapeutic

BioAxone Therapeutic is a clinical-stage biopharmaceutical company focused on developing treatments for neurotrauma and neurovascular disorders. Founded in 2000 by Dr. Lisa McKerracher, the company originated as a spin-out from a Canadian university. Dr. McKerracher, a serial entrepreneur and a recognized leader in translational neuroscience, transitioned from a 15-year academic career at McGill University and Université de Montréal to lead the company, leveraging her deep expertise in axon regeneration and Rho/ROCK signaling. Her work in the field has been recognized with multiple awards, including the Christopher Reeve Research Medal for Spinal Cord Repair.

The company's business model centers on the discovery, development, and subsequent out-licensing of its drug candidates to larger pharmaceutical partners for late-stage clinical trials and commercialization. This strategy is exemplified by the licensing of its ROCK2 inhibitor portfolio, including the lead compound NRL-1049 (formerly BA-1049), to Neurelis for the treatment of cerebral cavernous malformations (CCM). BioAxone has secured funding through various means, including venture capital, with investors like Desjardins Group and Fonds de solidarité FTQ, and has also been successful in obtaining over $6 million in non-dilutive SBIR grant funding from the NIH.

BioAxone's pipeline is built on a profound understanding of neuronal signaling pathways. A key focus is inhibiting the Rho pathway, which becomes hyperactivated after central nervous system trauma, preventing axon regeneration. Its lead candidate, BA-210 (Cethrin), is a Phase 3-ready, topically applied biologic Rho inhibitor designed to promote axon regeneration after acute spinal cord injury. BA-210 has received both Orphan Drug and Fast Track designations from the FDA. Another program targets cerebral cavernous malformation, a genetic disease causing leaky blood vessel clusters in the brain, with the orally available ROCK2 inhibitor NRL-1049. This drug aims to restore the integrity of the blood-brain barrier. Additionally, the company is developing BA-434, a preclinical self-delivering RNAi compound that targets PTEN, another protein that inhibits axon regeneration in adult neurons.

Source: Dealroom company data

BioAxone Therapeutic in the Montreal ecosystem

Live from Dealroom

The BioAxone Therapeutic office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇦 Canada · Montreal HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BioAxone Therapeutic on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BioAxone Therapeutic on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.